The federal regulatory tracker records an October 14 submission that remained pending review on October 16. The filing does not establish which peptides would qualify or demonstrate their safety and effectiveness.
Three editions daily.
Updated as the evidence changes.
The randomized comparison found no significant advantage over lifestyle education on its primary endpoint. Secondary findings warrant further investigation.
Researchers connect marrow fat, inflammation and impaired bone formation in preclinical experiments. The findings identify a potential research target, while leaving human benefits and safety unresolved.
Researchers report a chemical route to structures relevant to antimicrobial discovery. Earlier biological studies show why making these molecules is only one step toward establishing medical usefulness.
A randomized study across 13 hospitals found no significant mortality benefit from recommending vasopressin at a lower treatment threshold. The findings inform hospital practice while leaving smaller differences and individualized approaches unresolved.
Conceptual scientific illustration.
Not presented as study evidence.
Every consequential story carries a visible evidence grade, a primary-source trail and a plain-language account of what remains unknown.
Read our standards →Timely enough to matter.
Structured enough to be reliable.
Overnight research, journals and regulatory notices
Study analysis, explainers and claim checks
Breaking developments, context and what comes next
